Biokin’s SystImmune Receives Second USD 250 Million Milestone from BMS for Iza‑Bren – Cumulative Payments Reach USD 1.3 Billion with Up to USD 7.1 Billion Still Contingent

Fineline Cube
4 Min Read
Summarize with AI

Biokin Pharmaceutical (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune has received a second milestone payment of USD 250 million from Bristol-Myers Squibb (BMS) (NYSE: BMY) under their collaboration on iza‑bren (izalontamab brengitecan) — the world’s first approved EGFR×HER3 bispecific antibody‑drug conjugate (ADC).

- Advertisement -

Deal Economics Snapshot

ItemDetail
PartiesSystImmune (wholly‑owned subsidiary of Biokin Pharmaceutical, SHA: 688506) × Bristol Myers Squibb (NYSE: BMY)
AgreementExclusive license and collaboration agreement, signed December 2023
AssetIza‑bren (izalontamab brengitecan) – EGFR×HER3 bispecific ADC
Latest PaymentSecond milestone payment of USD 250 million
Payments Received to DateUSD 1.3 billion total (USD 800 million non‑refundable, non‑creditable upfront + first USD 250 million milestone + second USD 250 million milestone)
Remaining Contingent ValueUp to an additional USD 7.1 billion upon specified development, regulatory, and sales milestones
Announcement Date18 Nov 2026

Drug Profile & Regulatory Progress

  • Molecule: Iza‑bren (izalontamab brengitecan), an EGFR×HER3 bispecific antibody‑drug conjugate (ADC) — the world’s first approved EGFR×HER3 bispecific ADC, combining dual‑receptor targeting for enhanced tumor selectivity and internalization with a topoisomerase‑inhibitor payload class.
  • Partnership Foundation: In December 2023, Biokin’s subsidiary SystImmune entered into an exclusive license and collaboration agreement with BMS for iza‑bren, granting the US pharma major global development and commercialization rights.
  • China Approvals: In June and July 2026, iza‑bren was successively approved in China for the treatment of nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC) — establishing the bispecific ADC as a marketed therapy in two hard‑to‑treat solid tumors.
  • Milestone Economics: Prior to this payment, the company had already received an USD 800 million non‑refundable, non‑creditable upfront payment and the first USD 250 million milestone payment; Biokin remains eligible for up to an additional USD 7.1 billion in contingent payments tied to development, regulatory, and sales milestones.

Market Impact & Outlook

  • Landmark China Biotech Deal: With USD 1.3 billion already banked against a potential total exceeding USD 8.7 billion, the SystImmune–BMS agreement ranks among the most consequential out‑licensing deals ever struck by a China‑originated biotech, and the second milestone confirms continued value crystallization post‑approval.
  • First‑in‑Modality Validation: As the world’s first approved EGFR×HER3 bispecific ADC, iza‑bren validates the bispecific ADC architecture as a commercial reality — not just a scientific concept — differentiating it amid a crowded landscape of single‑target conjugates.
  • Revenue‑Linked Upside: The remaining contingent payments are increasingly weighted toward sales milestones, meaning Biokin’s future receipts are directly tied to iza‑bren’s commercial trajectory in NPC, ESCC, and potential future indications under BMS’ global development.
  • Balance‑Sheet Impact: The USD 250 million cash inflow strengthens Biokin’s capacity to fund its internal pipeline without dilution; specific use‑of‑proceeds plans and financial statement treatment were not disclosed beyond the payment confirmation.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Biokin–SystImmune–BMS collaboration on iza‑bren, including future milestone achievements, regulatory filings, and commercialization prospects. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review timelines across geographies, competitive dynamics in ADC therapeutics, and commercial adoption in nasopharyngeal and esophageal cancers. Contingent milestone payments are not guaranteed and may never be achieved in full.

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *